Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Saved in:
| Title: | Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. |
|---|---|
| Authors: | Furuhashi, Masato1 (AUTHOR) furuhasi@sapmed.ac.jp, Sakuma, Ichiro2 (AUTHOR), Morimoto, Takeshi3 (AUTHOR), Higashiura, Yukimura1 (AUTHOR), Sakai, Akiko1 (AUTHOR), Matsumoto, Megumi1 (AUTHOR), Sakuma, Mio3 (AUTHOR), Shimabukuro, Michio4 (AUTHOR), Nomiyama, Takashi5 (AUTHOR), Arasaki, Osamu6 (AUTHOR), Node, Koichi7 (AUTHOR), Ueda, Shinichiro8 (AUTHOR) |
| Source: | Cardiovascular Diabetology. 6/15/2020, Vol. 19 Issue 1, p1-10. 10p. 4 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
